GRCE today
$1.82-$0.03 (-1.88%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourAscending Triangle
1 hourStrong Bullish
15 minLeaning Bearish
5 minConsolidating
Daily trend turns up above $5.18
Key levels
Resistance$2.22
Resistance$2.05
Support$1.67
Latest news & SEC filings
SEC FilingGrace Therapeutics, Inc. filed a report on a major company event (Form 8-K)
SEC FilingGrace Therapeutics, Inc. filed an insider trading report (Form 4)
All GRCE news →About Grace Therapeutics
Grace Therapeutics is a pharmaceutical company developing treatments for rare and orphan diseases using proprietary drug delivery technologies. Its lead candidate, GTx-104, is an injectable form of nimodipine for aneurysmal subarachnoid hemorrhage, a type of stroke, intended for intravenous use in hospital intensive care settings. The company also has earlier-stage candidates for ataxia-telangiectasia in children and postherpetic neuralgia pain, though it is currently focused on GTx-104. It operates primarily in the United States.
Based on the company's 10-K filed Jun 18, 2026.
Nasdaq · Healthcare
Grace Therapeutics, Inc. (GRCE)
What Is the Price Target for GRCE?
SEPT Low Target
$8.00
SEPT Mid Target
$8.00
SEPT High Target
$8.00
Analyst Consensus
$8.00
Is GRCE a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GRCE.
Start Free Trial →Is GRCE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$7.82
12
Moat Score
NONE
2/9
Piotroski Score
1.5
Altman Z-Score
What Is Smart Money Doing with GRCE?
Insider Signal
BUYING
13 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% owner | Buy | 3,087 | $5K | Nov 5, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 5,027 | $9K | Nov 4, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 10,328 | $18K | Nov 3, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 4,256 | $8K | Oct 19, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 36,347 | $69K | Oct 16, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 23,485 | $46K | Oct 15, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 11,233 | $22K | Oct 14, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 1,694 | $3K | Oct 5, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 20,000 | $41K | Oct 2, 2026 |
| Opaleye Management Inc. | 10% owner | Buy | 38,796 | $79K | Oct 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GRCE Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
40.51%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for GRCE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GRCE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:49:52 | $1.82 | 1,350 | $$2K | SELL |
| 15:49:11 | $1.81 | 1,000 | $$2K | SELL |
| 20:40:54 | $1.89 | 8,337 | $$16K | BUY |
| 17:58:36 | $1.88 | 1,200 | $$2K | SELL |
| 20:56:20 | $1.88 | 6,000 | $$11K | BUY |
5 dark pool trades shown · $$34K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Grace Therapeutics, Inc. (GRCE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GRCE — frequently asked questions
What is GRCE stock price today?
Grace Therapeutics, Inc. (GRCE) is at $1.82, down 1.88% (-$0.03) at the Nov 12, 2026 close.
Why is GRCE stock moving today?
Latest GRCE news — Nov 12, 2026: Grace Therapeutics, Inc. filed a report on a major company event (Form 8-K) · Nov 5, 2026: Grace Therapeutics, Inc. filed an insider trading report (Form 4)
What is the GRCE price target?
The average analyst price target for GRCE is $8.00, ranging from $8 to $8, based on 1 analysts. Latest: TD Cowen maintains on Apr 24, 2026.
What do analysts rate GRCE?
Analyst ratings for GRCE: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did GRCE beat earnings?
GRCE last reported on Aug 13, 2026: EPS -$0.91 vs -$0.13 expected — a miss of 603.8%.
Does GRCE pay a dividend?
GRCE does not currently pay a dividend.
What are GRCE support and resistance levels?
Support: $1.67. Resistance: $2.05, $2.22, $2.36.
What are insiders doing with GRCE?
Insider activity: BUYING, 13 buys and 0 sells in the last 90 days.
What is the latest news on GRCE?
Nov 12, 2026: Grace Therapeutics, Inc. filed a report on a major company event (Form 8-K) · Nov 5, 2026: Grace Therapeutics, Inc. filed an insider trading report (Form 4)